Elanco Q2 revenue $1.184B, adjusted EPS $0.30; raises full-year revenue guidance

Elanco Animal Health Inc

2024-Q2 EPS reported -$0.04 revenue$2,389,000,000

Q2 revenue $1.184B (+12% reported, +13% CC); pet health $579M (+12%), farm animal $594M (+13%).
Adjusted EPS $0.30 (+67% YoY); adjusted EBITDA $275M (23.2% margin) vs $222M (21.0%).
Full year organic CC revenue growth guidance raised to 3%-4% (from 2%-3%); adjusted EPS maintained at $0.88-$0.96.
Aqua divestiture closed July 9, ~$1.2B proceeds used to pay down debt; gross debt reduced to ~$4.5B; net leverage 5.6x.
Zenrelia FDA final 60-day review; approval expected late Sept. Bovaer commercial activities underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.